At a glance
ClinicalIndex Comparison RecordN/ACompleted· 18 enrolled
Drug / intervention
Observation onlyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma
In Brief
An observational study evaluating Observation only for Glaucoma. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This is an open-label, observational extension of patients who received POLAT-001 in LipoLat-CS202.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
First PostedNov 2015
Primary CompletionJun 2016
TodayJul 2026
First PostedNov 6, 2015
Enrollment StartNov 1, 2015
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.7 years ago
Interventions
Observation onlyother
No intervention in this study.